MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 12-16-2023
Biohaven Pharmaceutical Holding Company Ltd. ROA Ratio 2011-2026 | BHVN
Annual ROA Ratio Biohaven Pharmaceutical Holding Company Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -78.59 | -111.62 | -153.6 | -83.07 | -86.59 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -78.59 | -153.6 | -102.7 |
Quarterly ROA Ratio Biohaven Pharmaceutical Holding Company Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -72.27 | -55.59 | -70.78 | -63.86 | -66.6 | -98.3 | -108.07 | -125.75 | -131.77 | -143.43 | -149.31 | -167.97 | -153.6 | -129.13 | -119.47 | -71.7 | -83.07 | -82.63 | -90.66 | -103.29 | -89.31 | -165.15 | -240.53 | -239.6 | -235.03 | -140.76 | -36.16 | -10.92 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -10.92 | -240.53 | -115.88 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-868.81 | - | -19.68 % | $ 18.4 M |  Canada |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-7.29 | $ 0.9 | -2.33 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
19.07 | $ 21.96 | -0.68 % | $ 3.64 B | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
-53.95 | $ 1.02 | -0.49 % | $ 428 M |  Israel |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Aligos Therapeutics
ALGS
|
-27.33 | $ 6.4 | 4.4 % | $ 63.3 M | USA |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-206.68 | - | 17.91 % | $ 11.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 21.41 | 1.9 % | $ 1 B | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-70.51 | $ 12.26 | 3.72 % | $ 1.62 B |  Australia |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 105.46 | -0.09 % | $ 27.2 B | Germany |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.08 | 0.25 % | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 23.26 | 1.75 % | $ 2.96 B | USA |
 |
Cara Therapeutics
CARA
|
-56.79 | - | -3.03 % | $ 260 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.44 | -5.88 % | $ 383 M | Britain |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
-155.62 | $ 1.06 | -3.64 % | $ 12.9 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-26.5 | - | - | $ 35.4 M | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 2.95 | -3.28 % | $ 296 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.91 | -1.36 % | $ 4.79 M | Israel |
 |
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |